The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to the drug.

A federal lawsuit and new scrutiny from Mexico’s tequila regulator have upended the booming “additive-free” tequila movement, calling into question how transparency claims are used on bottles and in ...